Drug Profile


Alternative Names: Gd-DTPA-BMEA; MP 1177; OptiMARK

Latest Information Update: 19 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mallinckrodt Medical
  • Class Contrast media; Organometallic compounds; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed CNS disorders; Liver disorders
  • No development reported Myocardial infarction

Most Recent Events

  • 20 Jul 2017 Mallinckrodt withdraws the phase III SHERLOC trial in Kidney disorders prior to enrolment because of unavailability of the study drug in USA (IV) (NCT00811863)
  • 10 Jul 2017 Guerbet announces intention to withdraw sales of gadoversetamide in the European Union starting 26 July 2017 and to phase out in other geographies by 2019
  • 10 Mar 2017 EMA's Pharmacovigilance Risk Assessment Committee recommends suspension of gadoversetamide from the market in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top